These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16704830)

  • 1. Isoniazid preventive therapy and risk for resistant tuberculosis.
    Balcells ME; Thomas SL; Godfrey-Faussett P; Grant AD
    Emerg Infect Dis; 2006 May; 12(5):744-51. PubMed ID: 16704830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    Kunkel A; Crawford FW; Shepherd J; Cohen T
    AIDS; 2016 Nov; 30(17):2715-2723. PubMed ID: 27782966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.
    Hermans SM; Grant AD; Chihota V; Lewis JJ; Vynnycky E; Churchyard GJ; Fielding KL
    BMC Med; 2016 Mar; 14():45. PubMed ID: 27004413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.
    Luabeya KK; Tameris MD; Geldenhuys HD; Mulenga H; Van Schalkwyk A; Hughes EJ; Toefey A; Scriba TJ; Hussey G; Mahomed H; McShane H; Landry B; Hanekom WA; Hatherill M
    Pediatr Infect Dis J; 2015 Nov; 34(11):1218-22. PubMed ID: 26252568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
    Velayati AA; Farnia P; Masjedi MR; Hoffner S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176
    [No Abstract]   [Full Text] [Related]  

  • 8. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.
    Mills HL; Cohen T; Colijn C
    Sci Transl Med; 2013 Apr; 5(180):180ra49. PubMed ID: 23576815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    Nagu TJ; Aboud S; Matee MI; Maeurer MJ; Fawzi WW; Mugusi F
    J Antimicrob Chemother; 2017 Mar; 72(3):876-881. PubMed ID: 27999054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Isoniazid-Resistant Tuberculosis in Homeless Shelters, Georgia, USA, 2015-2017.
    Holland DP; Alexander S; Onwubiko U; Goswami ND; Yamin A; Mohamed O; Sales RM; Grant G; Talboy P; Ray S; Toomey KE
    Emerg Infect Dis; 2019 Mar; 25(3):593-595. PubMed ID: 30789335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.
    Karo B; Kohlenberg A; Hollo V; Duarte R; Fiebig L; Jackson S; Kearns C; Ködmön C; Korzeniewska-Kosela M; Papaventsis D; Solovic I; van Soolingen D; van der Werf MJ
    Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
    van Halsema CL; Fielding KL; Chihota VN; Russell EC; Lewis JJ; Churchyard GJ; Grant AD
    AIDS; 2010 Apr; 24(7):1051-5. PubMed ID: 20299958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.
    Cohen T; Lipsitch M; Walensky RP; Murray M
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7042-7. PubMed ID: 16632605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ayele HT; Mourik MS; Debray TP; Bonten MJ
    PLoS One; 2015; 10(11):e0142290. PubMed ID: 26551023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
    Liu Z; Shilkret KL; Finelli L
    Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.
    Churchyard GJ; Chaisson RE; Maartens G; Getahun H
    S Afr Med J; 2014 Apr; 104(5):339-43. PubMed ID: 25212199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
    Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
    Sanchez-Padilla E; Ardizzoni E; Sauvageot D; Ahoua L; Martin A; Varaine F; Adatu-Engwau F; Akeche G; Salaniponi F; Bonnet M
    Int J Tuberc Lung Dis; 2013 Aug; 17(8):1036-42. PubMed ID: 23827027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.